Replies to post #1415 on RespireRx Pharmaceuticals Inc (RSPI)

[gfp927z]

Aiming, The thing with AD is that a high impact is the way to go. Low impacts like CX-717 will probably only provide symptomatic relief, although based on the lack of current treatments that could still be something big (just look at junk like Aricept, and only slightly better Namenda).

Ideally it would be best to save the neurodegenerative rights for when Cortex has a proven high impact in the clinic, but Cortex needs the money now and is thus forced to lose the rights. On the bright side, we can still do some type of high impact deal later with the BP (for the compound), even though the neurodegenerative rights are gone.